Insider Selling: United Therapeutics Corp. COO Sells 10,000 Shares of Stock (UTHR)

Share on StockTwits

United Therapeutics Corp. (NASDAQ:UTHR) COO Roger Jeffs sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $96.61, for a total transaction of $966,100.00. Following the completion of the transaction, the chief operating officer now directly owns 897 shares in the company, valued at approximately $86,659. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on UTHR shares. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $91.07.

United Therapeutics Corp. (NASDAQ:UTHR) opened at 97.66 on Monday. United Therapeutics Corp. has a one year low of $52.98 and a one year high of $116.65. The stock’s 50-day moving average is $107.6 and its 200-day moving average is $87.85. The company has a market cap of $4.905 billion and a P/E ratio of 17.66.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Netflix Set to Increase Subscription Price
Netflix Set to Increase Subscription Price
Hasbro Profit Helped by Girls Toys
Hasbro Profit Helped by Girls Toys
LinkedIn Reaches Milestone of 300 Million Members
LinkedIn Reaches Milestone of 300 Million Members
IBM Revenues Disappoint For Another Quarter
IBM Revenues Disappoint For Another Quarter
Walmart Enters the Business of Money Transfers
Walmart Enters the Business of Money Transfers
Google Stock Plummets on Earnings
Google Stock Plummets on Earnings


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+. Subscribe